In response to the unfortunate deaths of at least 141 children globally linked to cough syrups, the Drug Controller General of India (DCGI) has implemented a ban on the use of a combination of anti-cold medications in children below the age of four. Additionally, the DCGI has mandated proper labelling for drugs and has communicated with all states, urging them to update the package inserts for products containing a combination of chlorpheniramine maleate and phenylephrine. Pharmaceutical companies, including GlaxoSmithKline's T-Minic Oral Drops, Glenmark's Ascoril Flu Syrup, and IPCA Laboratories' Solvin Cold Syrup, among others, have been instructed by the regulatory body to include a 'warning' on their products.
#ColdFluBan #ChildSafety #HealthAlert #IndianGovernment #MedicationWarning #ChildrensHealth #SafetyFirst #HealthCareUpdate #ParentingNews #PublicHealth #KidsWellness #RegulatoryAction #DrugSafety #StayInformed #HealthDirective #ChildrensMedication #ColdAndFluSyrups #SafetyMeasures #HealthGuidelines #ChildHealthcare
~HT.178~GR.123~PR.152~ED.101~
